A Startup Just Raised $120 Million to Make Gene Editing Medications
Editas Medicine hopes to use CRISPR—a revolutionary new gene-editing technology—to treat conditions such as sickle-cell anemia, cancer, and cystic fibrosis. As MIT Technology Review reports, the influx of capital “reflects a surge of interest in CRISPR,” a powerful gene cutting-and-pasting tool that’s poised to revolutionize medicine. Editas, founded by a number of gene-editing pioneers, can…